MedPath

Evaluation of Mirtazapine and Folic Acid for Schizophrenia:A Large Simple 2x2 Factorial Trial.

Phase 1
Conditions
Schizophorenia with suboptimal responce to standard antipsychotics.
Registration Number
EUCTR2009-014469-19-FI
Lead Sponsor
Oxford University
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
ot Recruiting
Sex
All
Target Recruitment
53
Inclusion Criteria

diagnosis of DSM-IV schizophrenia
? active psychotic symptoms – i.e. hallucinations, delusions, thought disorder
? not meeting criteria for current manic episode including schizoaffective disorder
? inpatient or outpatient
? aged 16 to 70 years.
? able and willing to consent to participate
? currently taking effective dose of antipsychotic (see Appendix 1 for dose ranges)
? no antidepressant treatment within last two weeks and not considering treatment for depression
? not taking clozapine
? clinically appropriate to change or augment treatment*
? adjunctive mirtazapine appears reasonable and both investigator and patient are uncertain whether it will offer any benefit
Are the trial subjects under 18? no
Number of subjects for this age range:
F.1.2 Adults (18-64 years) yes
F.1.2.1 Number of subjects for this age range
F.1.3 Elderly (>=65 years) yes
F.1.3.1 Number of subjects for this age range

Exclusion Criteria

- contraindication to investigational medicinal products
- pregnancy, breast-feeding or planning a pregnancy

Study & Design

Study Type
Interventional clinical trial of medicinal product
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Secondary Outcome Measures
NameTimeMethod
© Copyright 2025. All Rights Reserved by MedPath